Research

Dr. Barbosa has conducted research across a broad array of therapeutic areas. Areas include:

Alzheimer's Disease

Dr. Barbosa's interest in Alzheimer's Disease stems from seeing his great aunt succumb to the disease and recognizing the effect it had not only on his great aunt, but also his mother who was a caregiver for her at the time. Dr. Barbosa currently collaborates with faculty and students at Ave Maria University.

Kidney Disease

Dr. Barbosa's efforts at 149 Bio, LLC are focused on discovery efforts to develop breakthrough medicines to treat kidney diseases. The current disease areas of focus are diabetic nephropathy, lupus nephritis, alport syndrome, focal segmental glomerulosclerosis, and nephrotic syndrome.

Cancer

Much of Dr. Barbosa's efforts in the field of cancer were as the Director of Chemistry with Adhaere Pharmaceuticals. The work involved discovery and development efforts around a novel series of CD11b agonists targeting solid tumors such as pancreatic, lung, breast and skin cancers. Adhaere Pharmaceuticals was sold to Gossamer Bio which is moving the lead compound into clinical trials for pancreatic, esophageal, gastric, triple negative breast, castration-resistant prostate, and microsatellite stable colorectal cancers.

Immunology and Inflammation

Much of Dr. Barbosa's work in the areas of Inflammation and Immunology was performed while he was at Boehringer Ingelheim Pharmacueticals and CGI Pharmacueticals. His research efforts spanned many biological targets such as cell surface adhesion molecules, GPCRs and kinases targeting diseases such as arthritis, psoriasis, multiple sclerosis, and Crohn's disease.